Therefore, BRCA1/2 testing or broader genetic panels could be more efficiently popularized and implemented in cost-effective screening and risk-reducing strategies, contributing to the genetic epidemiology of breast cancer, enforcing its management both at a regional and national level, and providing optimal therapeutic options for patients harboring germline PVs, given the current availability of personalized therapy for these variants such as PARP inhibitors. The gene discussed is BRCA1; the disease is breast cancer.